Press releases 2019 2019-08-26 Australian Minister for Health announced PBS listing of Buvidal® Weekly and Monthly for treatment of opioid dependence 2019-07-23 Camurus announces positive outcome of US court proceeding about final approval of Brixadi™ 2019-07-18 Interim Report January-June 2019 2019-07-16 Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan 2019-06-20 Camurus receives IND acceptance from the FDA to enter Phase 3 with CAM2029 for treatment of acromegaly 2019-06-04 Camurus announces publication of Phase 3 study results showing long-term safety, efficacy and high rates of patient satisfaction with Buvidal® 2019-05-09 Resolutions at the annual general meeting 2019 in Camurus 2019-05-09 Camurus Interim Report January-March 2019 2019-05-07 Camurus to present Interim report January-March 2019 on 9 May 2019-04-15 Camurus Annual Report for 2018 2019-04-09 Braeburn initiates court proceedings to overturn exclusivity and seeks immediate market approval of Brixadi™ in the US 2019-04-06 Positive treatment results for Buvidal® in fentanyl users presented at the ASAM 50th Annual Conference 2019-04-05 Notice of annual general meeting 2019 in Camurus AB (publ) 2019-03-29 Change in number of shares and votes in Camurus 2019-03-27 Camurus’ rights issue oversubscribed 2019-03-26 New date for publication of Camurus’ Annual Report 2018 2019-03-08 Camurus publishes prospectus relating to the rights issue 2019-03-05 Resolutions at the Extraordinary General Meeting in Camurus 2019-02-28 Camurus announces the terms of its rights issue 2019-02-14 Camurus to present at the Cowen and Company Annual Healthcare Conference 2019 2019-02-06 Full year report 2018 2019-02-06 Notice of extraordinary general meeting in Camurus AB (publ) 2019-02-06 Camurus to progress commercialization of Buvidal and advance pipeline programs through a fully underwritten rights issue of SEK 400 million 2019-02-01 Camurus to present full year 2018 results on 6 February 2019-01-18 Camurus to present at SEB Biotech Seminar in Stockholm 2019-01-11 Buvidal® launched as the first long-acting opioid dependence treatment in the EU 2018 2018-12-23 US FDA issues a tentative approval of Brixadi™ (buprenorphine) extended-release injection for treatment of opioid use disorder 2018-12-11 Camurus Capital Markets and R&D Day 11 December 2018 2018-11-28 Buvidal® Weekly and Buvidal® Monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence 2018-11-28 Program for Camurus Capital Markets and R&D Day 11 December 2018 2018-11-22 Camurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opioid dependence 2018-10-25 Interim Report January-September 2018 2018-10-16 Camurus’ Nomination Committee appointed for the Annual General Meeting 2019 2018-10-10 Camurus to present at Jefferies 2018 London Healthcare Conference 2018-10-09 Save the date: Camurus Capital Markets and R&D Day 11 December 2018 2018-09-21 CHMP recommends approval of Buvidal® (CAM2038) for the treatment of opioid dependence 2018-09-18 Camurus announces positive topline Phase 3 results for CAM2038 in opioid experienced patients with chronic low-back pain 2018-07-17 Interim Report January-June 2018 2018-07-16 Camurus announces PDUFA date for CAM2038 for the treatment of opioid use disorder 2018-06-29 Change in the number of shares and votes in Camurus AB 2018-06-29 Camurus has completed a directed share issue of 1.1 million shares, raising proceeds of approximately SEK 102 million 2018-06-28 Camurus updates its investor relations website 2018-06-28 Camurus intends to launch a directed share issue of approx. MSEK 100 2018-06-12 Camurus and Medison enter into commercialization agreement for CAM2038 in Israel 2018-05-31 Camurus announces positive topline results from Phase 1 study of long-acting treprostinil for the treatment of pulmonary arterial hypertension 2018-05-28 Camurus announces NDA resubmission of weekly and monthly buprenorphine depots to FDA 2018-05-25 Camurus to present at the Jefferies 2018 Global Healthcare Conference 2018-05-14 JAMA Internal Medicine publishes positive Phase 3 pivotal study results for Camurus’ long-acting buprenorphine depots for opioid use disorder 2018-05-03 Resolutions at the annual general meeting 2018 in Camurus 2018-05-03 Interim Report January-March 2018 2018-05-03 Camurus regains worldwide development and commercialization rights to CAM2029 and related product candidates 2018-03-23 Notice of annual general meeting 2018 in Camurus AB (publ) 2018-03-22 Camurus Annual Report for 2017 2018-03-08 Camurus to present at the Cowen and Company Annual Healthcare Conference 2018 2018-02-15 Full year report 2017 2018-01-21 FDA issues complete response letter for CAM2038 for opioid use disorder 2017 2017-12-21 First cohort dosed in Phase 1 clinical study of sustained release treprostinil injection for treatment of PAH 2017-11-07 Camurus to present at Jefferies 2017 London Healthcare Conference 2017-11-01 Camurus announces that FDA advisory committee recommends approval of CAM2038 for treatment of opioid use disorder 2017-10-30 Camurus announces that FDA has posted briefing material for CAM2038 Advisory Committee meeting 2017-10-26 Interim Report January-September 2017 2017-10-20 Nomination Committee appointed in respect of AGM 2018 in Camurus 2017-09-29 Camurus announces European Medicines Agency validation of CAM2038 Marketing Authorization Application for treatment of opioid dependence 2017-09-18 Camurus Announces that FDA Grants Priority Review of NDA for Weekly and Monthly CAM2038 Buprenorphine Depots for Treatment of Opioid Use Disorder 2017-07-20 Camurus and Braeburn Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder 2017-07-13 Interim report January-June 2017 2017-07-12 Camurus and Braeburn Pharmaceuticals Announce Topline Phase 2 Results for Long-acting Buprenorphine in Opioid Dependent Patients with Chronic Pain 2017-06-27 Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity 2017-06-22 Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder 2017-06-15 Camurus and Braeburn Pharmaceuticals Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine 2017-05-03 Resolutions at the annual general meeting 2017 in Camurus 2017-05-03 Interim Report January-March 2017 2017-05-02 Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038 2017-03-31 Camurus appoints VP Corporate Development & General Counsel 2017-03-30 Camurus Annual Report for 2016 released 2017-03-30 Notice of annual general meeting 2017 in Camurus AB (publ) 2017-03-09 Ethypharm and Camurus sign agreement for distribution of episil® in France 2017-02-16 Full year report 2016 2017-02-02 Camurus to present at the Cowen and Company Annual Healthcare Conference 2017 2017-01-09 Camurus to present at the J.P. Morgan Annual Healthcare Conference 2017 2016 2016-12-14 Camurus Capital Markets and R&D Day 2016 2016-11-25 Program for Camurus’ Capital Markets and R&D Day 14 December 2016 2016-11-14 Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine for Treatment of Opioid Addiction 2016-11-11 Camurus to provide an update on the progress of its research and development programs at the Jefferies 2016 Healthcare Conference 2016-11-08 Interim report January-September 2016 2016-11-01 Camurus to host a Capital Markets Day 14 December 2016 2016-10-28 Nomination Committee appointed in respect of AGM 2017 in Camurus 2016-10-24 Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to include New Combination Product for Pain and Nausea 2016-10-21 Braeburn Pharmaceuticals and Camurus announce the presentation of new data from clinical studies of long-acting buprenorphine 2016-09-30 Braeburn Pharmaceuticals and Camurus Enroll First Patients in a Phase 3 Efficacy Trial of CAM2038 for treatment of Chronic Low Back Pain 2016-07-14 Interim report January-June 2016 2016-07-12 Camurus announces completion of Phase 2 study of CAM2029 in patients with acromegaly and neuroendocrine tumors 2016-06-21 Camurus announces results from a Phase 2 trial of CAM2032 in patients with prostate cancer 2016-06-20 Richard Jameson assumes position as Camurus’ Chief Commercial Officer 2016-05-17 Camurus Interim Report January-March 2016 2016-05-11 Braeburn Pharmaceuticals and Camurus announce positive results from Phase 2 opioid challenge study with CAM2038 in subjects with opioid use disorder 2016-05-03 Resolutions at the Annual General Meeting 2016 in Camurus 2016-04-21 Distribution agreement signed with R-PHARM US for episil® 2016-04-05 Braeburn Pharmaceuticals and Camurus announce Enrollment goals reached in two pivotal Phase 3 Trials of CAM2038 for treatment of opioid dependence 2016-03-30 Notice of annual general meeting 2016 and proposal for new incentive program in Camurus AB (publ) By continuing to use the site, you agree to the use of cookies. more information Accept The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Close